Skip to content
DataLookout
Menu

NCT06809400

A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease

StatusRecruiting
PhasePhase 1
Primary completion (estimated)

At risk: Primary completion moved at least 8 months later, enrollment reduced 29%.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 16 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Jan 2028 to Oct 2028
    • Eligibility criteria expanded, about 34 words
    • Enrollment reduced: 127 → 90 participants
    • Study description expanded, about 2 words
  2. Minor Site details revised at 10 of 14 sitesv17
  3. Notable Eligibility criteria expanded, about 50 words
    • Site contacts updated at 1 of 14 sites
    v16
  4. Minor Site details revised at 1 of 14 sitesv15
  5. Minor Study sites: 13 to 14v13
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Site details revised at 1 of 13 sitesv12
  2. Minor Site contacts updated at 1 of 13 sitesv11
  3. Minor Study sites: 14 to 13v10
  4. Minor Study sites: 13 to 14v9
  5. Notable Eligibility criteria expanded, about 36 wordsv8
  6. Minor Secondary endpoints: 4 to 6v7
  7. Minor Site contacts updated at 1 of 13 sitesv6
  8. Notable Eligibility criteria revisedv5 Show 4 more changesShow less
    • Primary endpoints revised (4)
    • Primary and study completion dates: Nov 2027 to Jan 2028
    • Secondary endpoints revised (4)
    • Study sites revised (13)
  9. Minor Study sites: 2 to 13v4
  10. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: May 2028 to Nov 2027
    • Start date changed from estimate of Feb 2025 to Feb 18, 2025
    • Site details revised at 2 of 2 sites
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Part A
Timeframe: Baseline to Week 48
Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) Part A
Timeframe: Baseline to Week 48
Number of Participants with One or More SAEs Part B
Timeframe: Baseline to Week 61
Number of Participants with One or More TEAEs Part B
Timeframe: Baseline to Week 61

Secondary (6)

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY4006896 ARC-Associated Antisense Part A
PK: Cmax of LY4006896 ARC-Associated Antisense Part B
PK: Area Under the Concentration versus Time Curve (AUC) of LY4006896 ARC-Associated Antisense Part A
PK: AUC of LY4006896 ARC-Associated Antisense Part B
Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Skin Part B
Show 1 moreShow less
Effect of LY4006896 on Aggregation-Competent Alpha-Synuclein in Cerebrospinal Fluid (CSF) Part B

Arms and interventions

Part A LY4006896 + PlaceboExperimental

Healthy participants will receive a single escalating dose of LY4006896 and matching placebo.

Part B LY4006896 + PlaceboExperimental

Participants with Parkinson's disease will receive multiple doses of LY4006896 and matching placebo.

Drugs: LY4006896, Placebo

Sites

14 sites in 2 countries

United States 12, Japan 2